BeOne Medicines (NASDAQ:ONC) Releases Quarterly Earnings Results, Beats Expectations By $0.65 EPS

BeOne Medicines (NASDAQ:ONC) posted its quarterly earnings data on Wednesday. The company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.65, Zacks reports. The firm had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.66 billion. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%.

Here are the key takeaways from BeOne Medicines’ conference call:

• Q2 results exceeded expectations: Revenue reached $1.7 billion, up 30% year over year, while GAAP diluted EPS increased 144% to $2.05. The company raised 2026 revenue guidance by $300 million and GAAP operating-income guidance by $250 million.
• BRUKINSA continued its strong commercial momentum, generating more than $1.2 billion in global revenue, up 31%, with the highest sustained new-patient starts since launch and growth across all five approved indications. Management cited improving adherence, favorable early treatment duration and supportive real-world survival data.
• Pipeline and regulatory progress accelerated. FDA approval of BEQALZI in relapsed/refractory mantle cell lymphoma and positive Phase III MANGROVE results support a potential chemo-free frontline MCL regimen, with global submissions planned for the second half of 2026; several solid-tumor assets are also moving toward pivotal trials.
• The CELESTIMO 301 zanubrutinib/sonrotoclax regimen did not achieve statistical superiority on the uMRD endpoint versus venetoclax/obinutuzumab. The study will continue to its primary progression-free-survival endpoint, but the result introduces uncertainty despite management’s confidence in eventual PFS superiority.
• BeOne plans substantial continued investment in its pipeline, with 2027 operating expenses expected to grow at a rate similar to recent years. The company also announced a $300 million expansion of its Hopewell, New Jersey manufacturing site, while noting potential future biosimilar competition for XGEVA in its Amgen portfolio.

BeOne Medicines Price Performance

BeOne Medicines stock traded up $1.69 during mid-day trading on Thursday, reaching $329.22. The company had a trading volume of 186,427 shares, compared to its average volume of 280,046. The stock’s 50-day simple moving average is $294.53 and its 200-day simple moving average is $308.67. BeOne Medicines has a 1 year low of $253.95 and a 1 year high of $385.22. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The company has a market capitalization of $36.12 billion, a P/E ratio of 73.51 and a beta of 0.49.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Truist Financial raised their target price on shares of BeOne Medicines from $416.00 to $418.00 and gave the stock a “buy” rating in a research note on Thursday. Royal Bank Of Canada lowered their price objective on BeOne Medicines from $451.00 to $450.00 and set an “outperform” rating on the stock in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a report on Friday, July 17th. Guggenheim upped their price objective on BeOne Medicines from $420.00 to $430.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of BeOne Medicines in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, BeOne Medicines currently has an average rating of “Moderate Buy” and a consensus target price of $400.00.

More BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Q2 earnings beat estimates: BeOne reported earnings of $2.05 per share, well above the $1.40 consensus estimate, while revenue reached $1.71 billion versus expectations of $1.66 billion. The earnings beat supports the view that the company’s oncology portfolio is delivering stronger profitability. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook was raised: Management now expects full-year revenue of $6.6 billion to $6.8 billion, above Wall Street’s $6.5 billion forecast. Reports also indicated that second-quarter revenue surged 30%, reinforcing expectations for continued commercial momentum. BeOne Medicines raises 2026 outlook
• Positive Sentiment: Analysts raised targets and maintained bullish ratings: Guggenheim raised its target to $430 and Truist lifted its target to $418, both with Buy ratings. Citizens JMP raised its target to $405 with a Market Outperform rating. RBC trimmed its target slightly to $450 but retained an Outperform rating. These targets imply substantial upside from recent trading levels. Analyst rating updates
• Positive Sentiment: Pipeline progress: BeOne’s liver-cancer bispecific received a UK Innovation Passport, potentially supporting faster regulatory engagement and development. UK Innovation Passport announcement
• Neutral Sentiment: Insider sale appears administrative: CFO Aaron Rosenberg sold 1,157 shares worth approximately $362,000 to cover tax withholding related to vested equity awards. The transaction is therefore a limited bearish signal. SEC insider transaction filing

Insider Transactions at BeOne Medicines

In related news, SVP Chan Henry Lee sold 1,044 shares of BeOne Medicines stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $323.69, for a total transaction of $337,932.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 61,397 shares of BeOne Medicines stock in a transaction on Tuesday, July 21st. The stock was sold at an average price of $317.67, for a total value of $19,503,984.99. Following the transaction, the chief executive officer directly owned 9,180 shares of the company’s stock, valued at approximately $2,916,210.60. This represents a 86.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 345,561 shares of company stock worth $105,625,947 over the last quarter. Insiders own 6.19% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ONC. Cetera Investment Advisers purchased a new stake in shares of BeOne Medicines in the 2nd quarter worth about $455,000. Rhumbline Advisers acquired a new stake in shares of BeOne Medicines in the second quarter valued at approximately $275,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $505,000. Invesco Ltd. purchased a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $422,000. Finally, EverSource Wealth Advisors LLC acquired a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $68,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.